Zimberelimab drug page Clinical trials

Trials with Zimberelimab

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

3Trials
1Recruiting
7Countries
318Planned patients

Showing 1–3 of 3

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Recruiting Phase 2 43 patients NCT05024097

Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidat…

United States Mar 2022 – Dec 2031 Interventional
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
Finished Phase 1 227 patients NCT04660812

This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.

United States, France, Italy, South Korea and 2 more May 2021 – Sept 2025 Interventional
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Finished Phase 1 48 patients NCT03629756

This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with zimberelimab (AB122)…

United States, Australia Jul 2018 – Sept 2021 Interventional
Combined with: Etrumadenant

Where the recruiting trials are